Rendement sur 1 an (CAGR)
-12.41%
Sanofi SA Exchange (PA, EUR)
SAN.PA
79.74
+0.64 (+0.85%)
HealthcareDrug Manufacturers - General
Loading...
Rendement sur 3 ans (CAGR)
-3.65%
Rendement sur 5 ans (CAGR)
-2.07%
Rendement sur 10 ans (CAGR)
0.06%
Adobe 3e trimestre 2026 – Le sentiment du marché influence-t-il le prix ?
Lire plusCapitalisation boursière
91.23B
Cours/chiffre d'affaires
1.90
Valeur d'entreprise
144.38B
Cours/valeur comptable
1.31
Rendement du div
0.00%
Années de croissance
-
Croissance du div
-
Versement FCF
62.02%
Trailing P/E
13.50
PEG
-
P/E prévisionnel
8.38
Croissance EPS
-8.21%
Informations sur les actions
Qu'est-ce qu'une bourse ? Fonctionnement, acteurs, exemples
Lire plusGraphique boursier
Loading...
Données du prix des actions
| Ouverture | 76.00 |
| Max journalier | 76.66 |
| Min journalier | 75.74 |
| Volume journalier | 3.10M |
| Niveau record | 109.62 |
| Estimation des analystes sur 1 an | 94.06 |
| Beta | 0.28 |
| EPS (TTM) | 5.65 |
| Dividende par action | 0.00 |
| Date ex-div | 5 May 2026 |
| Prochaine date de bénéfices | 23 Apr 2026 |
Potentiel de baisse
Loading...
Données du potentiel de baisse
| SAN.PA | S&P500 | |
| Baisse de prix actuelle par rapport au niveau record | -27.26% | -3.00% |
| Baisse de prix actuelle la plus importante | -55.80% | -56.47% |
| Date de la baisse la plus importante | 10 Oct 2008 | 9 Mar 2009 |
| Baisse moyenne par rapport au record | -19.79% | -10.65% |
| Délai moyen pour nouveau record | 44 days | 12 days |
| Délai max pour nouveau record | 2908 days | 1805 days |
Actualite
Sanofi walked into its Q3 2026 report with the share price at €79.74 after a solid run over the past month, and the mood already leaning optimistic. The headline was clear: quarterly revenue landed at...
1 novembre 2026
An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.
31 octobre 2026
Shares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-quarter 2026 revenue to $5.1 billion, alongside a 70% rise in...
31 octobre 2026
Eurozone growth just cooled to 0.4% in Q3, yet still beat forecasts, and that mix of resilience and slowdown is quietly reshaping where money could flow next. Some businesses may benefit if investors ...
30 octobre 2026
Regeneron stock jumped to a two-year high Friday after its Sanofi-partnered inflammation giant, Dupixent, handily beat expectations.
30 octobre 2026
Sanofi (NASDAQ:SNY) reported third-quarter 2026 sales growth of 14.3% at constant exchange rates, supported by continued demand for Dupixent, recently launched medicines and growth in rare diseases. T...
30 octobre 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attr...
30 octobre 2026
European equities traded in the US as American depositary receipts were down 0.59% to 1,896.05 on th
30 octobre 2026